Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fatima Amanat and Florian Krammer.
Fatima Amanat
Connection Strength
10.224
Florian Krammer
  1. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. mBio. 2021 08 31; 12(4):e0100221.
    View in: PubMed
    Score: 0.959
  2. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021 07 22; 184(15):3936-3948.e10.
    View in: PubMed
    Score: 0.950
  3. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. mBio. 2021 03 02; 12(2).
    View in: PubMed
    Score: 0.932
  4. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020 09; 58(1):e108.
    View in: PubMed
    Score: 0.901
  5. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 07; 26(7):1033-1036.
    View in: PubMed
    Score: 0.882
  6. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 04 14; 52(4):583-589.
    View in: PubMed
    Score: 0.876
  7. Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model. Emerg Microbes Infect. 2019; 8(1):155-168.
    View in: PubMed
    Score: 0.802
  8. Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. mSphere. 2018 May-Jun; 3(3).
    View in: PubMed
    Score: 0.766
  9. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature. 2021 02; 590(7844):146-150.
    View in: PubMed
    Score: 0.228
  10. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA. 2020 06 16; 323(23):2424-2425.
    View in: PubMed
    Score: 0.222
  11. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020 06; 57(1):e100.
    View in: PubMed
    Score: 0.221
  12. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model. J Virol. 2017 08 15; 91(16).
    View in: PubMed
    Score: 0.182
  13. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J Virol. 2017 06 15; 91(12).
    View in: PubMed
    Score: 0.179
  14. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021 09 14; 54(9):2159-2166.e6.
    View in: PubMed
    Score: 0.060
  15. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021 08 18; 13(607).
    View in: PubMed
    Score: 0.060
  16. Corrigendum: Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine. Angew Chem Int Ed Engl. 2021 Jul 26; 60(31):16741-16742.
    View in: PubMed
    Score: 0.060
  17. Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses. 2021 07 15; 13(7).
    View in: PubMed
    Score: 0.060
  18. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. J Infect Dis. 2021 07 02; 224(1):70-80.
    View in: PubMed
    Score: 0.060
  19. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021 08; 596(7870):109-113.
    View in: PubMed
    Score: 0.060
  20. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep. 2021 06 25; 11(1):13308.
    View in: PubMed
    Score: 0.060
  21. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021 06 18; 12(1):3781.
    View in: PubMed
    Score: 0.059
  22. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.059
  23. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021 06 08; 54(6):1290-1303.e7.
    View in: PubMed
    Score: 0.059
  24. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. 2021 05 11; 54(5):1066-1082.e5.
    View in: PubMed
    Score: 0.059
  25. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021 04 01; 12(1):2037.
    View in: PubMed
    Score: 0.059
  26. Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell Death Dis. 2021 03 24; 12(4):310.
    View in: PubMed
    Score: 0.059
  27. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. Angew Chem Int Ed Engl. 2021 04 19; 60(17):9467-9473.
    View in: PubMed
    Score: 0.058
  28. Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. Clin Transl Immunology. 2021; 10(3):e1258.
    View in: PubMed
    Score: 0.058
  29. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. mBio. 2021 02 16; 12(1).
    View in: PubMed
    Score: 0.058
  30. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. 2021 03 16; 2(3):100208.
    View in: PubMed
    Score: 0.058
  31. Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit. Kidney Int. 2021 02; 99(2):484-486.
    View in: PubMed
    Score: 0.058
  32. A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2. Viruses. 2021 Jan 20; 13(2).
    View in: PubMed
    Score: 0.058
  33. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17; 8(4).
    View in: PubMed
    Score: 0.057
  34. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020 Dec; 9(1):2433-2445.
    View in: PubMed
    Score: 0.057
  35. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020 Dec; 62:103132.
    View in: PubMed
    Score: 0.057
  36. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity. 2020 12 15; 53(6):1281-1295.e5.
    View in: PubMed
    Score: 0.057
  37. Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients. Front Pediatr. 2020; 8:601327.
    View in: PubMed
    Score: 0.057
  38. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020 12 04; 370(6521):1227-1230.
    View in: PubMed
    Score: 0.057
  39. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk. iScience. 2020 Nov 20; 23(11):101735.
    View in: PubMed
    Score: 0.057
  40. A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2020 10 13; 222(10):1629-1634.
    View in: PubMed
    Score: 0.057
  41. Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks. Transfusion. 2020 10; 60(10):2457-2459.
    View in: PubMed
    Score: 0.057
  42. In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant. AJP Rep. 2020 Jul; 10(3):e270-e274.
    View in: PubMed
    Score: 0.056
  43. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020 11; 26(11):1708-1713.
    View in: PubMed
    Score: 0.056
  44. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 2020 11 12; 183(4):982-995.e14.
    View in: PubMed
    Score: 0.056
  45. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nat Commun. 2020 09 01; 11(1):4378.
    View in: PubMed
    Score: 0.056
  46. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. 2020 10 13; 53(4):724-732.e7.
    View in: PubMed
    Score: 0.056
  47. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020 08 15; 205(4):915-922.
    View in: PubMed
    Score: 0.056
  48. Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults. Clin Infect Dis. 2020 05 23; 70(11):2290-2297.
    View in: PubMed
    Score: 0.055
  49. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat Med. 2019 06; 25(6):962-967.
    View in: PubMed
    Score: 0.052
  50. Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice. PLoS One. 2018; 13(4):e0193680.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.